Heron Therapeutics
HRTX
173 hedge funds and large institutions have $242M invested in Heron Therapeutics in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 67 increasing their positions, 39 reducing their positions, and 38 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 39
39% more call options, than puts
Call options by funds: $297K | Put options by funds: $214K
5.72% less ownership
Funds ownership: 86.04% → 80.32% (-5.7%)
9% less funds holding
Funds holding: 190 → 173 (-17)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
47% less capital invested
Capital invested by funds: $454M → $242M (-$211M)
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.98M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.67M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.51M |
| 4 |
Morgan Stanley
New York
|
+$2.39M |
| 5 |
CC
Clearline Capital
New York
|
+$1.75M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$22.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$15.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.99M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.44M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.97M |
HRTX Hedge Fund Activity: Q3 2024 in Review
173 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2024, worth a combined $242M — down 47% from $454M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of HRTX and 21 opened new positions — a net loss of 17 holders — while 39 trimmed existing stakes and 67 added.
The largest buyer was Adage Capital Partners, adding an estimated $2.98M. The largest seller was OrbiMed, exiting entirely with an estimated $22.8M sold.
- 173 institutional investors held Heron Therapeutics (HRTX) as of Q3 2024, down from 190 in Q2 2024.
- Funds reported $242M of Heron Therapeutics stock for Q3 2024, down 47% quarter-over-quarter.
- 21 funds opened new Heron Therapeutics positions in Q3 2024 and 38 closed out, a net change of -17 holders.
- The largest Heron Therapeutics buyer in Q3 2024 was Adage Capital Partners, an estimated $2.98M added.
- The largest Heron Therapeutics seller in Q3 2024 was OrbiMed, an estimated $22.8M sold.
Based on aggregated 13F filings for Q3 2024.